Castle Biosciences, Inc. (NASDAQ: CSTL) Stock Competitors & Peer Comparison
See CSTL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CSTL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CSTL | $34.20 | +5.82% | 1B | -74.84 | -$0.44 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $629.27 | +0.27% | 233.8B | 27.16 | $23.16 | +0.29% |
| DHR | $218.85 | +1.36% | 153.9B | 27.43 | $7.98 | +0.66% |
| NTRA | $332.03 | +2.21% | 47.6B | -251.54 | -$1.32 | N/A |
| A | $159.00 | +1.73% | 44.9B | 27.36 | $5.81 | +0.63% |
| IDXX | $556.93 | +2.03% | 43.9B | 39.17 | $14.22 | N/A |
| IQV | $259.82 | +1.47% | 42.8B | 21.43 | $12.13 | N/A |
| ILMN | $219.40 | +2.89% | 33.2B | 43.62 | $5.03 | N/A |
| WAT | $410.70 | +1.49% | 30.7B | 30.03 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
CSTL vs DHR-PB Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CSTL's ROE is -0.04%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
CSTL vs TMO Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, TMO has a market cap of 233.8B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while TMO trades at $629.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas TMO's P/E ratio is 27.16. In terms of profitability, CSTL's ROE is -0.04%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CSTL is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
CSTL vs DHR Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, DHR has a market cap of 153.9B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while DHR trades at $218.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas DHR's P/E ratio is 27.43. In terms of profitability, CSTL's ROE is -0.04%, compared to DHR's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
CSTL vs NTRA Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, NTRA has a market cap of 47.6B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while NTRA trades at $332.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas NTRA's P/E ratio is -251.54. In terms of profitability, CSTL's ROE is -0.04%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, CSTL is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
CSTL vs A Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, A has a market cap of 44.9B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while A trades at $159.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas A's P/E ratio is 27.36. In terms of profitability, CSTL's ROE is -0.04%, compared to A's ROE of +0.21%. Regarding short-term risk, CSTL is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
CSTL vs IDXX Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, IDXX has a market cap of 43.9B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while IDXX trades at $556.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas IDXX's P/E ratio is 39.17. In terms of profitability, CSTL's ROE is -0.04%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, CSTL is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check IDXX's competition here
IQVIA Holdings Inc. (NYSE: IQV)
CSTL vs IQV Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, IQV has a market cap of 42.8B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while IQV trades at $259.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas IQV's P/E ratio is 21.43. In terms of profitability, CSTL's ROE is -0.04%, compared to IQV's ROE of +0.22%. Regarding short-term risk, CSTL is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check IQV's competition here
Illumina, Inc. (NASDAQ: ILMN)
CSTL vs ILMN Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, ILMN has a market cap of 33.2B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while ILMN trades at $219.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas ILMN's P/E ratio is 43.62. In terms of profitability, CSTL's ROE is -0.04%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, CSTL is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
CSTL vs WAT Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, WAT has a market cap of 30.7B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while WAT trades at $410.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas WAT's P/E ratio is 30.03. In terms of profitability, CSTL's ROE is -0.04%, compared to WAT's ROE of +0.02%. Regarding short-term risk, CSTL is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check WAT's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
CSTL vs MTD Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, MTD has a market cap of 28.2B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while MTD trades at $1,395.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas MTD's P/E ratio is 32.06. In terms of profitability, CSTL's ROE is -0.04%, compared to MTD's ROE of -12.00%. Regarding short-term risk, CSTL is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
CSTL vs LH Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, LH has a market cap of 27.6B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while LH trades at $336.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas LH's P/E ratio is 19.95. In terms of profitability, CSTL's ROE is -0.04%, compared to LH's ROE of +0.12%. Regarding short-term risk, CSTL is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
CSTL vs DGX Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, DGX has a market cap of 27B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while DGX trades at $244.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas DGX's P/E ratio is 24.10. In terms of profitability, CSTL's ROE is -0.04%, compared to DGX's ROE of +0.14%. Regarding short-term risk, CSTL is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
CSTL vs GH Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, GH has a market cap of 22.9B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while GH trades at $170.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas GH's P/E ratio is -48.91. In terms of profitability, CSTL's ROE is -0.04%, compared to GH's ROE of +2.11%. Regarding short-term risk, CSTL is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
CSTL vs EXAS Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas EXAS's P/E ratio is -95.37. In terms of profitability, CSTL's ROE is -0.04%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, CSTL is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
CSTL vs MEDP Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while MEDP trades at $620.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas MEDP's P/E ratio is 36.39. In terms of profitability, CSTL's ROE is -0.04%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, CSTL is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
CSTL vs ILMNV Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas ILMNV's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to ILMNV's ROE of N/A. Regarding short-term risk, CSTL is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
CSTL vs PKI Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas PKI's P/E ratio is 41.45. In terms of profitability, CSTL's ROE is -0.04%, compared to PKI's ROE of +0.03%. Regarding short-term risk, CSTL is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
CSTL vs CRL Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, CRL has a market cap of 14B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while CRL trades at $295.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas CRL's P/E ratio is 29.44. In terms of profitability, CSTL's ROE is -0.04%, compared to CRL's ROE of -0.08%. Regarding short-term risk, CSTL is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CRL's competition here
Revvity, Inc. (NYSE: RVTY)
CSTL vs RVTY Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, RVTY has a market cap of 13.9B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while RVTY trades at $124.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas RVTY's P/E ratio is 23.31. In terms of profitability, CSTL's ROE is -0.04%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, CSTL is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check RVTY's competition here
ICON Public Limited Company (NASDAQ: ICLR)
CSTL vs ICLR Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while ICLR trades at $172.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas ICLR's P/E ratio is 14.05. In terms of profitability, CSTL's ROE is -0.04%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, CSTL is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
CSTL vs QGEN Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, QGEN has a market cap of 9.1B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while QGEN trades at $44.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas QGEN's P/E ratio is 18.22. In terms of profitability, CSTL's ROE is -0.04%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, CSTL is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check QGEN's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
CSTL vs TWST Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, TWST has a market cap of 9.1B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while TWST trades at $145.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas TWST's P/E ratio is -65.58. In terms of profitability, CSTL's ROE is -0.04%, compared to TWST's ROE of -0.30%. Regarding short-term risk, CSTL is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check TWST's competition here
RadNet, Inc. (NASDAQ: RDNT)
CSTL vs RDNT Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, RDNT has a market cap of 6B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while RDNT trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas RDNT's P/E ratio is 167.00. In terms of profitability, CSTL's ROE is -0.04%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, CSTL is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
CSTL vs SHC Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, SHC has a market cap of 5.6B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while SHC trades at $19.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas SHC's P/E ratio is 20.39. In terms of profitability, CSTL's ROE is -0.04%, compared to SHC's ROE of +0.27%. Regarding short-term risk, CSTL is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
CSTL vs SYNH Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CSTL's ROE is -0.04%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check SYNH's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
CSTL vs BLLN Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, BLLN has a market cap of 4.4B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while BLLN trades at $95.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas BLLN's P/E ratio is 135.76. In terms of profitability, CSTL's ROE is -0.04%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check BLLN's competition here
GRAIL Inc. (NASDAQ: GRAL)
CSTL vs GRAL Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, GRAL has a market cap of 3.4B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while GRAL trades at $79.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas GRAL's P/E ratio is -8.16. In terms of profitability, CSTL's ROE is -0.04%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, CSTL is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check GRAL's competition here
Veracyte, Inc. (NASDAQ: VCYT)
CSTL vs VCYT Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, VCYT has a market cap of 3.4B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while VCYT trades at $42.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas VCYT's P/E ratio is 21.15. In terms of profitability, CSTL's ROE is -0.04%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, CSTL is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
CSTL vs OLK Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas OLK's P/E ratio is -96.59. In terms of profitability, CSTL's ROE is -0.04%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CSTL is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check OLK's competition here
Neogen Corporation (NASDAQ: NEOG)
CSTL vs NEOG Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while NEOG trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas NEOG's P/E ratio is 42.68. In terms of profitability, CSTL's ROE is -0.04%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, CSTL is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check NEOG's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
CSTL vs WGS Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while WGS trades at $87.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas WGS's P/E ratio is 241.85. In terms of profitability, CSTL's ROE is -0.04%, compared to WGS's ROE of -0.39%. Regarding short-term risk, CSTL is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check WGS's competition here
CareDx, Inc (NASDAQ: CDNA)
CSTL vs CDNA Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, CDNA has a market cap of 2.4B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while CDNA trades at $48.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas CDNA's P/E ratio is 55.94. In terms of profitability, CSTL's ROE is -0.04%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, CSTL is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
CSTL vs PSNL Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, PSNL has a market cap of 2B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while PSNL trades at $18.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas PSNL's P/E ratio is -16.86. In terms of profitability, CSTL's ROE is -0.04%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, CSTL is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
CSTL vs OPK Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while OPK trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas OPK's P/E ratio is -5.48. In terms of profitability, CSTL's ROE is -0.04%, compared to OPK's ROE of -0.06%. Regarding short-term risk, CSTL is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check OPK's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
CSTL vs GRALV Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas GRALV's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to GRALV's ROE of N/A. Regarding short-term risk, CSTL is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check GRALV's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
CSTL vs FLGT Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, FLGT has a market cap of 565.2M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while FLGT trades at $19.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas FLGT's P/E ratio is 1990.00. In terms of profitability, CSTL's ROE is -0.04%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, CSTL is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check FLGT's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
CSTL vs NEO Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, NEO has a market cap of 436.3M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while NEO trades at $16.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas NEO's P/E ratio is 130.62. In terms of profitability, CSTL's ROE is -0.04%, compared to NEO's ROE of -0.06%. Regarding short-term risk, CSTL is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
CSTL vs CO Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas CO's P/E ratio is 5.06. In terms of profitability, CSTL's ROE is -0.04%, compared to CO's ROE of +0.11%. Regarding short-term risk, CSTL is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check CO's competition here
Prenetics Global Limited (NASDAQ: PRE)
CSTL vs PRE Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, PRE has a market cap of 343.4M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while PRE trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas PRE's P/E ratio is -4.99. In terms of profitability, CSTL's ROE is -0.04%, compared to PRE's ROE of -0.49%. Regarding short-term risk, CSTL is less volatile compared to PRE. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check PRE's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
CSTL vs MYGN Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, MYGN has a market cap of 302.2M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while MYGN trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas MYGN's P/E ratio is -24.62. In terms of profitability, CSTL's ROE is -0.04%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, CSTL is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
CSTL vs FLDM Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CSTL's ROE is -0.04%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, CSTL is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check FLDM's competition here
Prenetics Global Limited (NASDAQ: PRENW)
CSTL vs PRENW Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, PRENW has a market cap of 260.1M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas PRENW's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, CSTL is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check PRENW's competition here
Biodesix, Inc. (NASDAQ: BDSX)
CSTL vs BDSX Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, BDSX has a market cap of 216.8M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while BDSX trades at $26.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas BDSX's P/E ratio is -8.40. In terms of profitability, CSTL's ROE is -0.04%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, CSTL is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
CSTL vs XGN Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, XGN has a market cap of 191.3M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while XGN trades at $7.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas XGN's P/E ratio is -9.78. In terms of profitability, CSTL's ROE is -0.04%, compared to XGN's ROE of -1.22%. Regarding short-term risk, CSTL is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
CSTL vs IMDX Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, IMDX has a market cap of 140.1M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while IMDX trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas IMDX's P/E ratio is -2.91. In terms of profitability, CSTL's ROE is -0.04%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, CSTL is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
CSTL vs GTH Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas GTH's P/E ratio is -1.11. In terms of profitability, CSTL's ROE is -0.04%, compared to GTH's ROE of -1.01%. Regarding short-term risk, CSTL is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
CSTL vs GENE Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas GENE's P/E ratio is -38.25. In terms of profitability, CSTL's ROE is -0.04%, compared to GENE's ROE of -1.85%. Regarding short-term risk, CSTL is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
CSTL vs SERA Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, SERA has a market cap of 81.7M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while SERA trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas SERA's P/E ratio is -3.29. In terms of profitability, CSTL's ROE is -0.04%, compared to SERA's ROE of -0.47%. Regarding short-term risk, CSTL is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
CSTL vs PRPO Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, PRPO has a market cap of 54.3M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while PRPO trades at $30.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas PRPO's P/E ratio is -117.12. In terms of profitability, CSTL's ROE is -0.04%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, CSTL is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
CSTL vs MDXH Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, MDXH has a market cap of 38.2M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while MDXH trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas MDXH's P/E ratio is -1.96. In terms of profitability, CSTL's ROE is -0.04%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, CSTL is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
CSTL vs QUCY Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, QUCY has a market cap of 29.6M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while QUCY trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas QUCY's P/E ratio is -0.06. In terms of profitability, CSTL's ROE is -0.04%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, CSTL is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
CSTL vs AKU Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas AKU's P/E ratio is -0.13. In terms of profitability, CSTL's ROE is -0.04%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CSTL is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
CSTL vs CEMI Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas CEMI's P/E ratio is -0.63. In terms of profitability, CSTL's ROE is -0.04%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, CSTL is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
CSTL vs ENZ Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas ENZ's P/E ratio is -2.24. In terms of profitability, CSTL's ROE is -0.04%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, CSTL is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
CSTL vs PMD Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas PMD's P/E ratio is -5.24. In terms of profitability, CSTL's ROE is -0.04%, compared to PMD's ROE of -0.32%. Regarding short-term risk, CSTL is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
CSTL vs ME Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas ME's P/E ratio is -0.03. In terms of profitability, CSTL's ROE is -0.04%, compared to ME's ROE of -42.03%. Regarding short-term risk, CSTL is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
CSTL vs MYNZ Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, CSTL's ROE is -0.04%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, CSTL is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check MYNZ's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
CSTL vs ADVB Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, ADVB has a market cap of 11.3M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while ADVB trades at $8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas ADVB's P/E ratio is -74.00. In terms of profitability, CSTL's ROE is -0.04%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, CSTL is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check ADVB's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
CSTL vs BNR Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, BNR has a market cap of 11.2M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while BNR trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas BNR's P/E ratio is -12.87. In terms of profitability, CSTL's ROE is -0.04%, compared to BNR's ROE of -0.11%. Regarding short-term risk, CSTL is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
CSTL vs CHEK Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas CHEK's P/E ratio is -0.43. In terms of profitability, CSTL's ROE is -0.04%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, CSTL is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
CSTL vs CNTG Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CSTL's ROE is -0.04%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CSTL is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check CNTG's competition here
Check-Cap Ltd. Ordinary Share (NASDAQ: MBAI)
CSTL vs MBAI Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, MBAI has a market cap of 8.1M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while MBAI trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas MBAI's P/E ratio is 12.07. In terms of profitability, CSTL's ROE is -0.04%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, CSTL is more volatile compared to MBAI. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check MBAI's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
CSTL vs APDN Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas APDN's P/E ratio is -0.10. In terms of profitability, CSTL's ROE is -0.04%, compared to APDN's ROE of -7.23%. Regarding short-term risk, CSTL is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
CSTL vs NDRA Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, NDRA has a market cap of 5.7M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while NDRA trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas NDRA's P/E ratio is -0.57. In terms of profitability, CSTL's ROE is -0.04%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, CSTL is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check NDRA's competition here
Invitae Corporation (NYSE: NVTA)
CSTL vs NVTA Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CSTL's ROE is -0.04%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, CSTL is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
CSTL vs LMDXW Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CSTL's ROE is -0.04%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CSTL is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
CSTL vs LMDX Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CSTL's ROE is -0.04%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CSTL is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
CSTL vs BIAFW Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, BIAFW has a market cap of 4.1M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while BIAFW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas BIAFW's P/E ratio is 0.44. In terms of profitability, CSTL's ROE is -0.04%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, CSTL is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
CSTL vs DMTK Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CSTL's ROE is -0.04%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, CSTL is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
CSTL vs NOTV Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas NOTV's P/E ratio is -0.03. In terms of profitability, CSTL's ROE is -0.04%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, CSTL is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
CSTL vs SQL Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas SQL's P/E ratio is -0.40. In terms of profitability, CSTL's ROE is -0.04%, compared to SQL's ROE of -30.46%. Regarding short-term risk, CSTL is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
CSTL vs AWH Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas AWH's P/E ratio is -0.09. In terms of profitability, CSTL's ROE is -0.04%, compared to AWH's ROE of +1.62%. Regarding short-term risk, CSTL is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check AWH's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
CSTL vs BIAF Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, BIAF has a market cap of 2.4M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while BIAF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas BIAF's P/E ratio is -0.05. In terms of profitability, CSTL's ROE is -0.04%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, CSTL is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BIAF's competition here
Intelligent Bio Solutions Inc. (NASDAQ: INBS)
CSTL vs INBS Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, INBS has a market cap of 1.6M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while INBS trades at $2.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas INBS's P/E ratio is -0.28. In terms of profitability, CSTL's ROE is -0.04%, compared to INBS's ROE of -1.70%. Regarding short-term risk, CSTL is less volatile compared to INBS. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check INBS's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
CSTL vs HTGM Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CSTL's ROE is -0.04%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CSTL is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
CSTL vs BIOC Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CSTL's ROE is -0.04%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CSTL is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
CSTL vs ISPC Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, ISPC has a market cap of 231.9K. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while ISPC trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas ISPC's P/E ratio is -0.05. In terms of profitability, CSTL's ROE is -0.04%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, CSTL is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
CSTL vs SQLLW Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, CSTL's ROE is -0.04%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, CSTL is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
CSTL vs WGSWW Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, CSTL's ROE is -0.04%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, CSTL is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check WGSWW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
CSTL vs MEUSW Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, CSTL is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
CSTL vs PRXL Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas PRXL's P/E ratio is 42.97. In terms of profitability, CSTL's ROE is -0.04%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, CSTL is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
CSTL vs OCDX Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CSTL's ROE is -0.04%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CSTL is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check OCDX's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
CSTL vs CHEKZ Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, CSTL is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check CHEKZ's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
CSTL vs NDRAW Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas NDRAW's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, CSTL is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check NDRAW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
CSTL vs BNGOW Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas BNGOW's P/E ratio is N/A. In terms of profitability, CSTL's ROE is -0.04%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, CSTL is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for CSTL.Check BNGOW's competition here
Danaher Corporation (NYSE: DHR-PA)
CSTL vs DHR-PA Comparison August 2026
Castle Biosciences, Inc. (NASDAQ: CSTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CSTL stands at 1B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CSTL is priced at $34.20 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CSTL currently has a P/E ratio of -74.84, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CSTL's ROE is -0.04%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, CSTL is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for CSTL.Check DHR-PA's competition here